EMA Grants Marketing Authorisation of mylife(TM) YpsoPump® for Use with NovoRapid® PumpCart®, Marking the Start of a Collaboration Between Novo Nordisk and Ypsomed

Bagsværd, Denmark (ots/PRNewswire) -

This material is intended for global medical media only.

For journalistic assessment and preparation before publication.

Novo Nordisk today announces the European Medicines Agency (EMA)
marketing approval of the mylife(TM) YpsoPump® insulin pump for use
with prefilled pump cartridge NovoRapid® PumpCart®. The approval is a
key milestone for the collaboration between Novo Nordisk and Ypsomed
and their goal to deliver innovative care solutions that improve the
lives of people with diabetes.

With its icon-based touch screen, mylife(TM) YpsoPump® by Ypsomed
is an insulin pump, designed to simplify therapy, which is fully
compatible with NovoRapid® PumpCart® by Novo Nordisk, the first
prefilled pump cartridge with an insulin analogue that has been
specifically designed for insulin pumps.

"Insulin pump therapy can be an effective option for helping some
people with diabetes, particularly those living with type 1 diabetes,
however, operating a traditional insulin pump, and manually filling
the insulin reservoir, can be complex and time-consuming," says Dr
Mark Evans, lecturer and honorary consultant in medicine at the
University of Cambridge. "Given these factors, and the burden put
upon health systems to train patients to use traditional pumps,
efforts to simplify the process are truly welcomed."

NovoRapid® PumpCart® contains NovoRapid® (insulin aspart), a
rapid-acting insulin from Novo Nordisk, and is a 1.6 ml prefilled
pump cartridge specifically designed to make insulin pump therapy
more convenient for some people with diabetes and the healthcare
professionals caring for them. It is compatible with insulin pump
mylife(TM) YpsoPump® by Ypsomed and has also been available with
Roche Diabetes Care's Accu-Chek® Insight insulin pump since November
2014 in select EU markets.

"Our partnerships with Ypsomed and Roche Diabetes Care enable us
to offer new options designed to simplify insulin pump therapy for
people living with diabetes and the healthcare professionals who
manage their care," said Christian Kanstrup, senior vice president,
marketing, medical affairs and stakeholder engagement at Novo
Nordisk.

NovoRapid® PumpCart® is currently available in the following EU
markets for use with the Accu-Chek® Insight pump: United Kingdom,
Sweden, Austria, Denmark, Netherlands, Germany, France, Czech
Republic and Italy.

mylife(TM) YpsoPump® received authorisation for use with prefilled
pump cartridge NovoRapid® PumpCart® on 24 June 2016. Healthcare
professionals interested in knowing in which countries mylife(TM)
YpsoPump® will be made available should contact Ypsomed directly.

About insulin pump therapy

An insulin pump delivers insulin from a reservoir inside the pump
to a patient's body using an infusion set and a tiny cannula. Insulin
pumps use bolus insulin, such as insulin aspart. The insulin is
delivered using continuous infusion and is often used by people with
type 1 diabetes who receive intensified insulin therapy and test
their blood glucose levels on a regular basis. An insulin pump is
suitable for certain patients and provides more flexibility, with the
potential to improve glycaemic control and quality of life[1],[2]. In
Europe, use of insulin pumps among people with type 1 diabetes
varies, with less than 5% using a pump in some countries and more
than 15% in other countries. In the US, 40% use a pump[3],[4].

About NovoRapid®

NovoRapid® (insulin aspart) is a mealtime insulin analogue
indicated for the treatment of diabetes mellitus in adults,
adolescents, children aged 2 years and above and can be used in
pregnancy. NovoRapid® has been available for use in Europe since 1999
and has launched in more than 120 countries.

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90
years of innovation and leadership in diabetes care. This heritage
has given us experience and capabilities that also enable us to help
people defeat other serious chronic conditions: haemophilia, growth
disorders and obesity. Headquartered in Denmark, Novo Nordisk employs
approximately 41,600 people in 75 countries and markets its products
in more than 180 countries. For more information, visit
novonordisk.com (http://www.novonordisk.com/), Facebook
(http://www.facebook.com/novonordisk), Twitter
(http://www.twitter.com/novonordisk), LinkedIn
(http://www.linkedin.com/company/novo-nordisk), YouTube
(http://www.Youtube.com/novonordisk)

Further information

Media:

Katrine Sperling

+45-4442-6718

krsp@novonordisk.com

Åsa Josefsson

+45-3079-7708

aajf@novonordisk.com

Investors:

Peter Hugreffe Ankersen

+45-3075-9085

phak@novonordisk.com

Melanie Raouzeos

+45-3075-3479

mrz@novonordisk.com

Kasper Veje (US)

+1-609-235-8567

kpvj@novonordisk.com

For information about mylife(TM) YpsoPump®, please contact Ypsomed
directly:

Benjamin Overney

+41-34-424-41-59

benjamin.overney@ypsomed.com

All trademarks used or mentioned in this release are legally
protected.

References:

1. Cohen ND, et al. Long-Term Metabolic Effects of Continuous
Subcutaneous Insulin Infusion Therapy in Type 1 Diabetes. Diabetes
Technology & Therapeutics 2013; 15(7):544-549.
2. Pickup JC. Management of diabetes mellitus: is the pump mightier
than the pen? Nature Reviews Endocrinology 2012; 8:425-433.
3. Clinical Audit and Registries Management Service. National
Diabetes Insulin Pump Audit 2013-15. Version 1. Health & Social
Care Information Centre. 1 April 2016. Available at: http://www.hq
ip.org.uk/public/cms/253/625/19/520/National%20Diabetes%20Insulin%
20Pump%20Audit%20report%202013-15.pdf?realName=hOfPw8.pdf?v=0
(Last accessed: 20 June 2016).
4. Pickup JC. Insulin pumps. International Journal of Clinical
Practice (Supplement) 2011; 170:16-19.

Internet: http://www.novonordisk.com

CVR no: 24 25 67 90

ZINC:
HQMMA/NR/0616/0165

Date of preparation: June 2016

ots Originaltext: Novo Nordisk A/S
Im Internet recherchierbar: http://www.presseportal.de